Though the baseline illness severity was uneven, with more severe patients in the itolizumab arm, the medication showed great ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to ...
Ulcerative colitis affects daily life, but proper management can help maintain quality of life. Learn how to cope with this ...
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...
Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a ...
Janus kinase (JAK) inhibitors can quickly and effectively manage ulcerative colitis (UC), especially when more conventional treatments haven’t worked. UC is a type of inflammatory bowel disease ...
Doctors believe new test could lead to earlier diagnoses and more effective treatment for thousands of patients ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
About 500,000 people in the UK live with inflammatory bowel disease (IBD), including Crohn's and ulcerative colitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results